SV

Street Verdict

Analyst Scorecard

A record of what Sumeet Bagadia said publicly, with the source. Not advice.

Pending — not yet graded
“Bullish on Suven Pharmaceuticals, recommending a buy at ₹1224 with a target of ₹1308 and a stop loss at ₹1179, based on strong technical charts.”

Sumeet Bagadia’s track record (trackable calls only): 1528 graded calls · 95% CI 32–37%

Cohance Lifesciences LimitedBullishCalled 03 Mar 2025
Verdict:PENDING

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.

Entry: ₹1,224, as stated.

Target ₹1,308, stop ₹1,179, as stated.

No time frame is stated, so it is tracked until a close reaches ₹1,308 or ₹1,179: there is no fixed window.

Waiting for a close to reach the entry.

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Tracking Cohance Lifesciences Limited since this call

1-year tracking window
Read the original articleSee Sumeet Bagadia’s full track record